Overview

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Status:
Completed

Trial end date:
2013-07-27

Target enrollment:

Participant gender:

Summary

This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Diego

Treatments:

Bevacizumab